Symposium: Helicobacter pylori and clinical risks-focus on gastro-oesophageal reflux disease

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 16, Issue 3, 2002, Pages 1-10

  Malfertheiner, P ^a,f   O'Connor, H J ^b   Genta, R M ^c   Unge, P ^d   Axon, A T R ^e  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b ADELAIDE AND MEATH HOSPITAL   (Ireland)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d Länssjukhuset Gävle Sandviken ^*  (Sweden)

^e LEEDS GENERAL INFIRMARY   (United Kingdom)

^f UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; METRONIDAZOLE; OMEPRAZOLE; TINIDAZOLE; ANTIULCER AGENT; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; CAGA PROTEIN, HELICOBACTER PYLORI; PROTON PUMP;

BACTERIAL FLORA; BACTERIAL INFECTION; BACTERIAL VIRULENCE; CONFERENCE PAPER; DISEASE ASSOCIATION; ERADICATION THERAPY; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HUMAN; INFECTION RISK; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NONHUMAN; PEPTIC ULCER; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; GENETICS; HELICOBACTER INFECTION; MICROBIOLOGY; PATHOGENICITY; RISK FACTOR;

ANTI-ULCER AGENTS; BACTERIAL PROTEINS; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMAN; PROTON PUMPS; RISK FACTORS; ANTIGENS, BACTERIAL; HUMANS;

EID: 0036094921     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (58)

1. Helicobacter pylori
2. Duodenal ulcer disease: A new infectious disease
3. Regression of primary low grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue (MALT) type after eradication of Helicobacter pylori
4. Helicobacter pylori
5. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia
6. Current European concepts in the management of Helicobacter pylori infections
7. Report of the 1997 Asia-Pacific Consensus Conference on the management of Helicobacter pylori infection
8. Helicobacter pylori in peptic ulcer disease
9. Helicobacter pylori and gastro-oesophageal reflux disease: Clinical implications and management
10. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction
11. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis
12. Helicobacter pylori, the cardia, and gastroesophageal reflux disease
13. Helicobacter pylori and gastroesophageal reflux disease: The bug may not be all bad
14. Decreased prevalence of Helicobacter pylori infection in gastroesophageal reflux disease
15. Does cure of Helicobacter pylori infection induce heartburn
16. Helicobacter pylori infection, pattern of gastritis, and symptoms in erosive and nonerosive gastroesophageal reflux disease
17. Curing Helicobacter pylori infection in patients with duodenal ulcer does not provoke gastroesophageal reflux disease
18. Helicobacter pylori infection has no role in the pathogenesis of reflux esophagitis
19. Prevalence of oesophagitis in H. pylori-positive peptic ulcer disease and the impact of eradication therapy
20. Helicobacter pylori infection is associated with milder gastro-oesophageal reflux disease
21. High prevalence of reflux symptoms in duodenal ulcer patients who develop gastro-oesophageal reflux disease after curing Helicobacter pylori infection
22. Hypothesis: The changing relationships of Helicobacter pylori and humans: Implications for health and disease
23. Colonization with cagA-positive Helicobacter pylori strains inverseley associated with reflux esophagitis and Barrett's esophagus
24. Not all Helicobacter pylori strains are created equal: Should all be eliminated?
25. Adenocarcinoma of the gastric cardia
26. The rising trend in oesophageal adenocarcinoma and gastric cardia
27. The gastric cardia in Helicobacter pylori infection
28. Rising incidence of adenocarcinoma of the esophagus and gastric cardia
29. Etiology of Barrett's metaplasia and esophageal adenocarcinoma
30. Helicobacter pylori: Current status
31. Immune response of the gastric mucosa to Campylobacter pylori
32. Lymphoid follicles in the antral mucosa: Immune response to Campylobacter pylori
33. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma
34. Helicobacter pylori eradication - Understandable caution but no excuse for inertia
35. Eradication of Helicobacter pylori in functional dyspepsia: A randomized, double-blind placebo controlled trial with 12 months follow-up: The Optimal Regimen Cures Helicobacter-induced Dyspepsia (ORCHID) study group
36. Treatment of Helicobacter pylori: Where are we now? What are the key questions?
37. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia
38. Modelling cost effectiveness of Helicobacter pylori screening to prevent gastric cancer: A mandate for clinical trials
39. Increased prevalence of Helicobacter pylori infection in critically ill patients with stress ulceration
40. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori
41. Helicobacter pylori eradication does not exaccrbate reflux symptoms in gastroesophageal reflux disease
42. Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: A randomised controlled trial
43. Helicobacter gastroduodenitis: A serious infectious disease
44. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease
45. Effects of eradication of Helicobacter pylori on gastritis in duodenal ulcer patients
46. Long-term treatment with omeprazole for refractory reflux esophagitis: Efficacy and safety
47. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy. Implications for long-term safety
48. Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole
49. 2-receptor antagonists and antacids have an aggravating effect on Helicobacter pylori gastritis in duodenal ulcer patients
50. Clinical and pathological importance of heterogeneity in vacA, the vacuolating cytotoxin gene of Helicobacter pylori
51. The only good Helicobacter pylori is a dead Helicobacter pylori (multiple letters)
52. Helicobacter pylori in gastro-oesophageal reflux disease: Causal agent, independent or protective factor?
53. Peptic esophagitis (a new clinical entity)
54. Chronic peptic ulcer of the oesophagus and 'oesophagitis'
55. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease
56. CagA-positive strains of Helicobacter pylori may protect against Barrett's esophagus